Alembic Pharmaceuticals Q1 FY27 call set for Aug 4, 2026

What the company has announced

Alembic Pharmaceuticals Limited has scheduled a post-results earnings conference call for Tuesday, August 4, 2026, at 5:30 PM IST. The call is planned after the company’s board meeting on the same day, where directors will consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company said the session will focus on operational and financial performance for Q1 FY27. The announcement was disclosed through filings to the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Ltd (NSE). The disclosure letter is dated July 27, 2026. The conference call, as described in the filing, is restricted to analysts and institutional investors.

Who can participate and why it matters

The company has positioned the conference call as a structured forum for analyst and institutional investor questions. Such calls typically help the market understand quarterly performance and the management’s commentary in one setting. In this case, Alembic’s filing explicitly states that management will address queries related to the latest quarterly performance. The schedule also aligns with a busy results season window for the quarter ending June 2026, which the text describes as “July-August 2026 (indicative)”. For investors tracking the stock, the call timing is relevant because it follows the board meeting where Q1 FY27 unaudited financials are expected to be taken up.

Board meeting and results discussion on August 4

As per the market snapshot included in the text, Alembic Pharmaceuticals has scheduled a board of directors meeting on August 4, 2026. The stated agenda is to consider and approve unaudited financial results for the first quarter ended June 30, 2026. The company will then host the earnings call at 5:30 PM IST on the same day. The filing frames the call as a post-results interaction, indicating it is linked to the quarter’s financial release. The notice also notes the discussion is intended for analysts and institutional investors.

Two ways to join: Diamond Pass registration

The company has provided two participation routes for the call. The first option is registration through the Diamond Pass portal. The filing states that this route provides dial-in numbers, passcodes, and a PIN directly to the registered email address. This is positioned as a simplified method for participants who prefer a single-step login and access details delivered by email. The text does not specify any additional eligibility checks beyond the “restricted” nature of the call for analysts and institutional investors.

Direct dial-in option across multiple regions

The second option is direct dial-in using universal access numbers or toll-free lines. The company has listed access numbers for India and several international regions, including the USA, the UK, Singapore, and Hong Kong. These numbers are intended to make participation easier for investors and analysts outside India as well. The filing provides two universal access numbers and separate toll-free lines by region.

Dial-in information (as disclosed)

Contact person and signatory

For further assistance, the company has named Isha Lamba as the contact person. The filing lists the phone number as +91 22-66951652 and email as isha.lamba@alembic.co.in. The disclosure letter dated July 27, 2026 is signed by G. Krishnan, the company’s Chief Financial Officer.

Where Alembic ended FY26: latest reported numbers cited

The text also provides a snapshot of Alembic’s recent financial base and shareholder actions for FY26. It states that Q4 FY26 consolidated revenue from operations stood at ₹1,847.72 crore, with year-on-year growth of 4.41% (also referenced as “up 4% YoY”). Consolidated net profit (PAT) for Q4 FY26 is stated at ₹202.70 crore, up 29.19% year-on-year from ₹156.89 crore in Q4 FY25. For the full year, FY26 consolidated revenue from operations is stated at ₹7,344.90 crore versus ₹6,672.08 crore in FY25.

The board also recommended a dividend of ₹12 per share (face value ₹2 each) for the financial year ended March 31, 2026. The record date for determining eligibility is stated as July 29, 2026.

Key figures mentioned in the text

Street expectations and price levels cited

Alongside the event notice, the text includes a preview-style estimate range for Q1 FY27. It cites a Q1 FY27E revenue range of ₹1,677-1,930 crore and a PAT estimate of ₹174-221 crore. The same section states the preview framework is built on a Q1 FY26 base of ₹1,717 crore revenue and ₹154 crore net profit, using the most recent year-on-year growth signal from Q4 FY26.

The text also cites Alembic Pharmaceuticals “CMP Rs.824” and a 12-month target range of ₹824-931 (labelled as a “Uniresearch estimate”). Separately, it mentions “Price ₹756” and says the stock trades at a P/E of 21.1 with a market cap of ₹15,413.

Market impact: what this event changes today

The immediate market relevance is event-driven rather than results-driven because the filing is about timing and access to the post-results call. For analysts and institutions, the announcement clarifies the schedule of the board meeting and the management interaction on August 4, 2026 at 5:30 PM IST. It also formalises the communication channel and the process to join through Diamond Pass or direct dial-in. For investors tracking FY26 performance and the dividend record date of July 29, 2026, the call provides the next structured checkpoint after the board considers Q1 FY27 unaudited results.

Why the details matter: access, transparency, and comparables

Conference call logistics matter because participation depends on correct access credentials and dial-in options, especially for international participants. The disclosed universal access numbers and toll-free lines reduce friction for institutions operating across geographies. The filing also adds transparency by naming the support contact and the signatory (the CFO).

From a financial context standpoint, the Q4 FY26 and FY26 numbers cited in the text form the recent base against which Q1 FY27 performance may be compared. The same compilation also includes an estimate range for Q1 FY27 revenue and PAT, and a stated price and target range, showing that the event is being tracked alongside near-term expectations.

Conclusion

Alembic Pharmaceuticals has set its Q1 FY27 post-results conference call for August 4, 2026 at 5:30 PM IST, following a board meeting to consider the unaudited June-quarter results. The company has provided Diamond Pass registration and direct dial-in options, including toll-free numbers across key regions. The next confirmed step is the board’s consideration of the Q1 FY27 unaudited financial results on August 4, 2026, followed by management’s interaction with analysts and institutional investors.